Full Life Christian Centre

Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals

Retrieved on: 
Friday, December 8, 2023
Automation, Patient, GMP, Full Life Christian Centre, Radiopharmaceutical, Good manufacturing practice, Gembloux

GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.

Key Points: 
  • GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.
  • This strategic investment aims to advance Full-Life's end-to-end solution by enhancing its radiopharmaceutical production capabilities at a key logistical hub to ensure the timely supply and delivery to patients worldwide.
  • The 4,000 square meter, state-of-the-art facility, which will serve as Full-Life's production hub, integrates sustainable design with automation and digital quality assurance systems.
  • The facility, which will sit on 17,000 square meters of land, is specifically tailored to produce a broad spectrum of radiopharmaceuticals.

Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production

Retrieved on: 
Thursday, May 4, 2023
GMP, Ecosystem, Full Life Christian Centre, Good manufacturing practice, Transport, Radiopharmaceutical, Vaccine

GEMBLOUX, Belgium, May 3, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.

Key Points: 
  • GEMBLOUX, Belgium, May 3, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
  • "Production capability and capacity, as well as logistics challenges have been major bottlenecks to radiotherapeutic discovery and development," said Philippe van Put, General Manager of Full-Life Technology Europe.
  • "The advanced GMP manufacturing facility we are building at this 17,000 square meter site, will provide us with an internal, integrated manufacturing solution and a strong competitive advantage."
  • The region is a leading hub for radiopharmaceutical production, and Full-Life will leverage its expertise and the local ecosystem to accelerate the facility's construction and GMP drug production.

Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production

Retrieved on: 
Thursday, May 4, 2023
GMP, Ecosystem, Full Life Christian Centre, Good manufacturing practice, Transport, Radiopharmaceutical, Vaccine

GEMBLOUX, Belgium, May 4, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.

Key Points: 
  • GEMBLOUX, Belgium, May 4, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
  • "Production capability and capacity, as well as logistics challenges have been major bottlenecks to radiotherapeutic discovery and development," said Philippe van Put, General Manager of Full-Life Technology Europe.
  • "The advanced GMP manufacturing facility we are building at this 17,000 square meter site, will provide us with an internal, integrated manufacturing solution and a strong competitive advantage."
  • The region is a leading hub for radiopharmaceutical production, and Full-Life will leverage its expertise and the local ecosystem to accelerate the facility's construction and GMP drug production.

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
IND, Radiopharmaceutical, Oncology, National Cancer Institute, Health, University, Lymphoma, Eli Lilly, Therapy, Merck Group, Merck, Germinal center B-cell like diffuse large B-cell lymphoma, Science, Master of Science, University Hospital Heidelberg, CD38, Organic chemistry, IPO, MD, FDA, Head, Chinese Academy of Sciences, NBE, Novo Nordisk, Boehringer Ingelheim, CSO, CD19, EGFR, RDC, Cancer, Full Life Christian Centre, Clinical trial, German Cancer Research Center, CMO, Acquisition, Doctor of Philosophy, Anti-CD19 immunotoxin, S.A, PSMA, Pharmaceutical industry, Lilly, Chemistry

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Key Points: 
  • MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
  • Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
  • "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
  • Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
IND, Radiopharmaceutical, Oncology, National Cancer Institute, Health, University, Lymphoma, Eli Lilly, Therapy, Merck Group, Merck, Germinal center B-cell like diffuse large B-cell lymphoma, Science, Master of Science, University Hospital Heidelberg, CD38, Organic chemistry, IPO, MD, FDA, Head, Chinese Academy of Sciences, NBE, Novo Nordisk, Boehringer Ingelheim, CSO, CD19, EGFR, RDC, Cancer, Full Life Christian Centre, Clinical trial, German Cancer Research Center, CMO, Acquisition, Doctor of Philosophy, Anti-CD19 immunotoxin, S.A, PSMA, Pharmaceutical industry, Lilly, Chemistry

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Key Points: 
  • MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
  • Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
  • "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
  • Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

Retrieved on: 
Friday, December 2, 2022
Dai, Peptide, Focus X, Full Life Christian Centre, CADD, CMC, Cryogenic electron microscopy, PCC, Radiopharmaceutical, Trust, Chemical substance, IIT, Therapy, Cancer, Research, ASMS, CSO, HDX, EFS, Toxicity, DNA, Patient, Acquisition, Euler's totient function, SPR, Head, Control, CIO, Antibody, Drug, PDC, Pharmaceutical industry, Fine chemical, Manufacturing

They completed their angel round in the third quarter of 2020, which was led by Viva.

Key Points: 
  • They completed their angel round in the third quarter of 2020, which was led by Viva.
  • In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
  • Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
  • Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.

Kunlun Capital Helps Medical Companies Grow in the Long Run

Retrieved on: 
Tuesday, July 12, 2022
Technology, Obio, Half-life, Company, Peptide, Patient, Full Life Christian Centre, Entrepreneurship, RMB, Radiopharmaceutical, Investment, Venture capital, Research, Growth, Cancer, KRKR, NASDAQ, USD, Cryptocurrency, Pharmaceutical industry

BEIJING, July 12, 2022 /PRNewswire/ --Recently, Yahui Zhou, the founding partner of Kunlun Capital, won the 36kr 2022 " China 100 Best Investors Voted by Entrepreneurs " award and Kunlun Capital won the 36kr 2022 " China 100 Best Venture Capital Voted by Entrepreneurs " award.

Key Points: 
  • BEIJING, July 12, 2022 /PRNewswire/ --Recently, Yahui Zhou, the founding partner of Kunlun Capital, won the 36kr 2022 " China 100 Best Investors Voted by Entrepreneurs " award and Kunlun Capital won the 36kr 2022 " China 100 Best Venture Capital Voted by Entrepreneurs " award.
  • Founded in 2015, Kunlun Capital focuses on investments in technology innovation companies and operates in a dual-currency model in USD and RMB.
  • In recent years, Kunlun Investment has been deeply engaged in the medical field and invested in many outstanding medical companies such as Keya Medical, EdiGene, Cytek (NASDAQ:CTKB) and OBiO (688238).
  • Kunlun Capital expects that Full-Life can bring benefits to more cancer patients and promote the development of medical technology,and will also help more medical companies grow in the long run.

Full-Life Technologies Announces Senior Executive Team Appointments

Retrieved on: 
Tuesday, January 4, 2022
Health, Manufacturing, Other Manufacturing, Radiology, Pharmaceutical, Biotechnology, Radiation, Therapy, Strategic planning, University, BLA, Acquisition, Novartis, Ovarian cancer, Director, Roivant Sciences, Nuclear energy, Research, Full Life Christian Centre, Patient, Citibank, The Universe (Catholic newspaper), University of Detroit Mercy, Silicon, Biochemistry, Cranial nerve nucleus, Control, Wharton School of the University of Pennsylvania, Abbott, AREVA, General manager, Engineering, IRE, ImmunoGen, CEO, Philippe, NASDAQ, Platinum, MBA, FDA, Institute, Partner (business rank), Nuclear technology, Board, Safety, Eli Lilly, Half-life, Radiopharmaceutical, Applied science, Biotechnology, Roche, Wendell Pritchett, ADC, Management, Fine chemical, Chemistry, Gordian

Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.

Key Points: 
  • Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.
  • He noted that the core executive team also includes Full-Life co-founder and Chief Operating Officer Nicholas Wong, Ph.D.
    Dr. Chari is an internationally renowned antibody-drug conjugate (ADC) expert .
  • Mr. Sun is a seasoned life science executive with more than a decade of experience and strong track record in biotechnology.
  • Full-Life Technologies Limited is a fully integrated global Nuclear Health company headquartered in Shanghai with operations in Europe.